News & Events
- Vedanta Biosciences Awarded $3.9 Million from CARB-X to Ready VE707 for First-in-Human Study for Prevention of Multidrug-Resistant Infections
- Vedanta Biosciences to Present at Upcoming Investor Conferences
- Genetic Analysis AS: Notice of Annual General Meeting 2024
- Genetic Analysis AS: Publication of Annual Report 2023
- Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
- Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference
- Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Year-end report January – December 2023
- Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024
- Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference
- Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz
- Genetic Analysis AS announces CE-IVDR marking for its GA-map® Sample Collection Kit
- Genetic Analysis AS: Genetic Analysis AS announces CE-IVDR marking for its GA-map® Sample Collection Kit
- Genetic Analysis subsequent offering to existing shareholders has now been registered with the Norwegian Register of Business Enterprises
- Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155